Finance Review Daily is tracking this developing story; further verified details were not immediately available.
Novartis Phase 3 Harbor trial for del-desiran (from Avidity acquisition) misses its primary endpoint in myotonic dystrophy type 1.
Finance Review Daily is tracking this development following a report from the original source. Finance Review Daily will provide updates as verified details become available.
Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.
More from Sophie Laurent →
